

GangaGen secures additional \$7.9 M from CARB-X to address infections caused by MDR *Klebsiella pneumoniae*

23 December 2024 | News

GangaGen is developing a new class of therapeutics called klebicins as precision agents to target *Klebsiella pneumoniae*



GangaGen has secured the third instalment of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), the global initiative led by Boston University to support the development of antibacterial products aimed at diagnosing, preventing, and treating drug-resistant infections.

The grant follows GangaGen's successful completion of Lead Optimisation milestones within its ongoing CARB-X partnership for its "Klebicin programme," which is designed to address infections caused by multidrug-resistant *Klebsiella pneumoniae*.

CARB-X has already committed \$7.9 million to support the Pre-clinical development of GangaGen's Klebicin project. Contingent of meeting specific milestones and subject to availability of funds, further funding may be available to advance the pre-clinical phase and demonstrate safety in human volunteers.

Tanjore S Balganes, President of GangaGen Biotechnologies, said, "Klebicins are protein antibacterials that specifically kill *Klebsiella pneumoniae*, a hard-to-treat pulmonary pathogen that is highly resistant to current antibiotics."

"This would be a big step forward for the company and we are extremely grateful to CARB-X for the continued partnership and support to develop klebicins for the treatment of pneumonia" added Vivek Daniel Paul, CSO of GangaGen Biotechnologies.